Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
04/2003
04/17/2003CA2463563A1 Kinase inhibitor scaffolds and methods for their preparation
04/17/2003CA2463507A1 Methods for the synthesis of substituted purines
04/17/2003CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors
04/17/2003CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound
04/17/2003CA2463170A1 Antiradicals and fat compositions, foods, drinks, drugs or feeds containing the antiradicals
04/17/2003CA2463049A1 Novel method of assaying immune activity
04/17/2003CA2462950A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors
04/17/2003CA2462913A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina
04/17/2003CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process
04/17/2003CA2462876A1 Compositions for and methods of treating and preventing sirs/sepsis
04/17/2003CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists
04/17/2003CA2462861A1 Piperidine compounds as muscarinic antagonists
04/17/2003CA2462858A1 Low molecular weight gtpase rhot
04/17/2003CA2462806A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide
04/17/2003CA2462801A1 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
04/17/2003CA2462582A1 Adjuvants for nucleic acid vaccines
04/17/2003CA2461961A1 Use of 2-oxo-1-pyrrolidine derivatives for the treatment of dyskinesia and movement disorders
04/17/2003CA2461900A1 Leukocyte inactivation module
04/17/2003CA2461655A1 Nogo receptor-mediated blockade of axonal growth
04/17/2003CA2461435A1 Angiopoietin-2 specific binding agents
04/17/2003CA2461369A1 Arylsulphonyl-substituted tetrahydro-and-hexahydro-carbazoles as 5-ht-6 receptor ligands
04/17/2003CA2461092A1 Pharmaceutical composition for the treatment of disorders of non-human mammals
04/17/2003CA2461064A1 Inhibition of stat-1
04/17/2003CA2460476A1 Protein modification and maintenance molecules
04/17/2003CA2458456A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract
04/17/2003CA2458453A1 Acylsulfonamides as inhibitors of steroid sulfatase
04/17/2003CA2458392A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them
04/16/2003EP1302476A1 Reduced fk228 and use thereof
04/16/2003EP1302472A1 Molecules capable of binding to telomere and the like and method with the use of the same
04/16/2003EP1302470A1 Lipid-rich plaque inhibitors
04/16/2003EP1302468A1 Processes and intermediates for manufacturing retroviral protease inhibiting compounds
04/16/2003EP1302461A1 Tnf-alpha production inhibitors
04/16/2003EP1302460A1 Indolecarboxylic compounds and their use as pharmaceutical compounds
04/16/2003EP1302458A1 Ester derivatives
04/16/2003EP1302203A1 Stem cell reinforcing material
04/16/2003EP1302201A1 Pharmaceutical composition improved in peroral absorbability
04/16/2003EP1301604A2 Substrates and assays for beta-secretase activity
04/16/2003EP1301602A2 Fh-binding protein of streptococcus pneumoniae
04/16/2003EP1301598A2 Cell cycle proteins and mitosis-associated molecules
04/16/2003EP1301595A2 G-protein coupled receptors
04/16/2003EP1301593A2 ANTISENSE COMPOSITIONS TARGETED TO $g(b) 1? ADRENOCEPTOR-SPECIFIC MRNA AND METHODS OF USE
04/16/2003EP1301541A2 Bifunctional molecules and vectors complexed therewith for targeted gene delivery
04/16/2003EP1301535A2 G-protein coupled receptors
04/16/2003EP1301528A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301527A2 Peptides as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies
04/16/2003EP1301522A1 Novel compounds and methods
04/16/2003EP1301516A1 Modulators of protein tyrosine phosphatases (ptpases)
04/16/2003EP1301514A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use
04/16/2003EP1301511A2 IMIDAZO 1,2-a]PYRAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
04/16/2003EP1301507A2 Mannich base prodrugs of 3 - (pyrrol-2-ylmethylidene)-2-indolinone derivatives and their use as modulators of protein kinases
04/16/2003EP1301506A1 Cyclic amino acid derivatives
04/16/2003EP1301505A2 Thiophene retinoids
04/16/2003EP1301500A1 Nitrosated and nitrosylated taxanes, compositions and methods of use
04/16/2003EP1301497A1 Colchinol derivatives as vascular damaging agents
04/16/2003EP1301495A2 Inhibitors of copper-containing amine oxidases
04/16/2003EP1301490A2 5-substituted 2-aryl-4-pyrimidinones
04/16/2003EP1301488A1 Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
04/16/2003EP1301487A2 Viral polymerase inhibitors
04/16/2003EP1301486A2 Imidazolidinones as ns3-serine protease inhibitors of hepatitis c virus
04/16/2003EP1301484A2 Capsaicin receptor ligands
04/16/2003EP1301482A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists
04/16/2003EP1301481A1 Pyrrole derivatives for treating aids
04/16/2003EP1301480A1 1,3-disubstituted and 1,3,3-trisubstituted pyrrolidines as histamine-3 receptor ligands and their therapeutic applications
04/16/2003EP1301476A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation
04/16/2003EP1301475A1 Aryl sulfonamides as serotonin antagonist for the treatment of obesity
04/16/2003EP1301474A2 Tyrosine derivatives as phosphatase inhibitors
04/16/2003EP1301213A2 Multi-component biological transport systems
04/16/2003EP1301210A2 Compositions containing therapeutically active components having enhanced solubility
04/16/2003EP1301193A1 Process for preparing composition comprising medicinal herb extract for preventing and curing arthritis and composition thereof
04/16/2003EP1301187A2 Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv
04/16/2003EP1301184A2 Valproic acid and derivatives thereof as histone deacetylase inhibitors
04/16/2003EP1301182A2 Use of matrix metalloprotease inhibitors for the treatment of cancer
04/16/2003EP1301181A2 Therapeutic and prophylactic use of reduced forms of pharmaceutical compounds
04/16/2003EP1301173A1 A medicinal aerosol formulation
04/16/2003EP1301076A2 Enhancing therapeutic effectiveness of nitric oxide inhalation
04/16/2003EP1301074A2 Uses for nad synthetase inhibitors
04/16/2003EP1181017B1 Metalloprotease inhibitors
04/16/2003EP1150981B1 Use of (1r, 4s)-4-(6-amino-9h-purin-9-yl)-2-cyclopentene-1-methanol in hbv
04/16/2003EP1150697B1 High molecular weight extracts of convolvulus arvensis (field bindweed)
04/16/2003EP1094812A4 Angiogenesis inhibitors
04/16/2003EP1086682B1 Utilization of aryl(or heteroaryl)azolylcarbinol derivatives in the preparation of a medicament for the treatment of neurogenic inflammation
04/16/2003EP1075478B1 Phenylurea and phenylthio urea derivatives
04/16/2003EP1054667B1 Bicyclic pyrrole compounds, pharmaceutical compositions containing them and their use as antiinflammatory and immunomodulating agents
04/16/2003EP1053240B1 Glucocorticoid-selective antiinflammatory agents
04/16/2003EP1040095B1 Cyclohexene carboxylates as neuraminidase inhibitors
04/16/2003EP1009442B1 Improvements in or relating to regulation of t cell activation
04/16/2003EP0991644B1 Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
04/16/2003EP0971913B1 Process for the production of semi synthetic statins via novel intermediates
04/16/2003EP0970083B1 7a-HETEROCYCLE-SUBSTITUTED HEXAHYDRO-1H-PYRROLIZINE COMPOUNDS USEFUL IN CONTROLLING CHEMICAL SYNAPTIC TRANSMISSION
04/16/2003EP0922045B1 Bicyclic pyrimidine derivatives and their use as anti-coagulants
04/16/2003EP0918455B1 Use of galanin to repair nerve damage
04/16/2003EP0873404B1 Angiotensin converting enzyme inhibitors
04/16/2003EP0869945B1 Catechol diethers derivatives useful as pharmaceutical agents
04/16/2003EP0824544B1 Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use
04/16/2003EP0792154B1 Composition of cisplatin in combination with 2,2'-dithio-bis(ethanesulfonate) (dimesna)
04/16/2003EP0769958B1 Inhibitors of leukocyte adhesion
04/16/2003EP0591462B1 Universal donor cells
04/16/2003CN1411512A Chimeric immunogenic compositions and nucleir acids encoding them
04/16/2003CN1411508A Oligonucleotides modulating expression of enzymes involved in synthesis of melanic pigments
1 ... 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 ... 1564